ArticleJournal of virology2015
Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.
Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant.Journal of virology · 2025Article
- LAIV Mutations Selectively Alter Influenza Viral RNA Polymerase Function, Favoring Transcription over Genome Synthesis.Viruses · 2025Article
- Abortive Infection of Animal Cells: What Goes Wrong.Annual review of virology · 2024Review
- Both Humoral and Cellular Immunity Limit the Ability of Live Attenuated Influenza Vaccines to Promote T Cell Responses.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups.Journal of virology · 2022Article
- Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine.Microbiology spectrum · 2022Article
- A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines.Viruses · 2021Article
- Article
- Article
- Impact of Pre-Existing Immunity on Live Attenuated Influenza Vaccine-Induced Cross-Protective Immunity.Vaccines · 2020Article
- A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.Journal of virology · 2020Article
- Article
- Lessons from next generation influenza vaccines for inflammatory disease therapies.International immunopharmacology · 2019Review
- A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections.Journal of virology · 2019Article
- Review
- Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 ProteinsFrontiers in microbiology · 2019Article
- Review
- Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.Drugs · 2018Review
- Article
- Incompatible Translation Drives a Convergent Evolution and Viral Attenuation During the Development of Live Attenuated Vaccine.Frontiers in cellular and infection microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.